Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

California Bill Targets Toxic Chemicals in Disposable Diapers

The bill would require manufacturers to list all intentionally added ingredients online and on diaper packaging by 2029.

California has introduced a bill aimed at making diaper manufacturers disclose all intentionally added chemicals in their products. Currently, business confidentiality shields companies from reporting on chemicals other than those posing a significant health risk. Assembly Bill 1901 requires manufacturers to publicly disclose all added ingredients and the specific reason for each by January 1, 2028, for diapers sold, distributed, or manufactured in California.

Companies would then need to print this information on all product packaging. The bill has received support from consumer safety organizations, including Consumer Reports and the Environmental Working Group, but faces opposition from the California Chamber of Commerce, the California Manufacturers & Technology Association, and the Center for Baby and Adult Hygiene Products, representing diaper manufacturers.

Diapers are expected to be used by an estimated 20 million women across the U.S. and can contain toxic substances like phthalates and PFAS. AB 1901 would set penalties of up to $5,000 for first violations and $10,000 for subsequent violations, with penalties accruing daily for continuing violations. The bill has already passed several California committees and is expected to reach the state Senate soon.

Written by urgent.news from Newsweek's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at newsweek.com →

More in Health & Medicine

Eight biotech companies in Melbourne you should know about

Discover 8 biotech companies in Melbourne, ranging from commercial to preclinical-stage companies, advancing promising technologies.

  • Telix Pharmaceuticals leads in radiopharmaceuticals with Illuccix for prostate cancer
  • Ena Respiratory develops INNA-051 to combat viral respiratory infections
  • Mesoblast receives FDA approval for Ryoncil to treat acute graft vs host disease in children

More from Monday 17 August →